About the CPD course
This module outlines the legislative and regulatory context for the development of generic drugs and describes the essential role of the Abbreviated New Drug Application (ANDA) in gaining marketing approval. The use of information in the ‘Orange Book’ is explained; as is the role of patent certification in the application. The importance of establishing bioequivalence between a generic and its reference product is emphasised. The module specifies the content and format requirements for an ANDA submission and describes the FDA’s review and approval process. An outline is given of the Generic Drug User Fee Amendments (GDUFA) and the law’s effects.
Send an enquiry
grapl
grapl is a UK based digital learning and development specialist, authoring and designing Zenosis® courses to provide an extensive eLearning library for the pharmaceutical, biotech and medicinal products sector. This learning can be delivered via the customers LMS, the grapl LMS or its social, knowledge and collaborative CloudRooms platform. Continuously updated to reflect regulatory changes, Zenosis® courses are trusted to educate their people by some of the worlds leading companies.
Want to learn more?
More CPD courses by grapl
Education
An Introduction to Drug Safety and Pharmacovigilan...
grapl
Drug safety monitoring and risk management are vitally important for medicinal product developers; l...
Online Course
Education
An Introduction to Clinical Trials and Drug Develo...
grapl
This course provides an understanding of how clinical trials fit into the drug development process....
Online Course
Education
An Introduction to Clinical Trial Preparation and...
grapl
Worldwide expenditure on R&D by the pharmaceutical industry is continually increasing. Most of the f...
Online Course
Education
ICH Good Clinical Practice
grapl
Good Clinical Practice (GCP) is a set of internationally recognised ethical and scientific quality r...
Online Course
Get industry-related content straight to your inbox
Thank you for subscribing
By signing up to our site you are agreeing to our privacy policy